GDPs and AGEs: Local and systemic effects in PD patients

Contributions to Nephrology

Volumn 140, Issue , 2003, Pages 38-46

  Ledebo, Ingrid ^a   Wieslander, Anders ^b   Deppisch, Reinhold ^b  

^a Gambro AB   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56249138993     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071422     Document Type: Article

References (18)

1. Ledebo I, Wieslander A, Kjellstrand P: Can we prevent the degradation of glucose in peritoneal dialysis solutions? Perit Dial Int 2000;20(suppl 2):48-51.
2. Wieslander A, Deppisch R, Svensson E, Forsbäck G, Speidel R, Rippe B: In vitro biocompatibility of a heat-sterilized, low-toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int 1995;15: 158-164.
3. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A: 3,4-Dideoxyglucosone-3-ene: A cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002;62: 697-703.
4. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
5. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes J: Alterations in non-enzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremie complications. Kidney Int 1999;55:389-399.
6. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jörres A: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-739.
7. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis J, Craig KJ, Williams JD, Topley N. Glucose degradation products retard re-mesothelialisation independently of D-glucose concentration. Kidney Int 2003 (submitted).
8. Bajo MA, del Peso G, Castro MA, Diaz C, Castro MJ, Gil F, Sánchez-Tomero JA, Seigas R: Effect of bicarbonate/lactate peritoneal dialysis solutions on human mesothelial cell proliferation ex vivo. Adv Perit Dial 2001;17:37-41.
9. Rippe B, Simonsen O, Wieslander A, Landgren C: Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int 1997; 17:27-34.
10. Cappelli G, Bandiani G, Cancarini GC, Feriani M, Dell' Aquila R, Saffioti S, Spisni C, Stingone A, Orazi E, Ballocchi S, Renaux JL: Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag. Adv Perit Dial 1999; 15:238-242.
11. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
12. Linden T, Musi B, Järkelid L, Forsbäck G, Kjellstrand P, Deppisch R, Wieslander A: Glucose degradation products in peritoneal dialysis fluids may have both local and systemic effects: A study of residual fluid and mesothelial cells. Perit Dial Int 2001;21:607-609.
13. Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, Uchida K, Saito A, van Ypersele de Strihou C, Kurokawa K: Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compound. Kidney Int 2000;58: 425-435.
14. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, Saito A, Kurokawa K, van Ypersele de Strihou C: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-2356.
15. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, van Ypersele de Strihou C, Kurokawa K: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999;463:260-264.
16. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
17. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen F-D, Bro S, Friedberg M, Wieslander A: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-357.
18. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N: Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001;21(suppl 3):102-107.